The Technical Analyst
Erytech Pharma S.A. [ERYP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Erytech Pharma S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.30% $0.780
America/New_York / 28 jun 2023 @ 15:48
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 47.38 mill |
| EPS: | -0.0100 |
| P/E: | -78.00 |
| Earnings Date: | Apr 26, 2023 |
| SharesOutstanding: | 60.75 mill |
| Avg Daily Volume: | 0.149 mill |
| RATING 2023-06-28 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | |||||
| Asset | n/a | n/a | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -78.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -13.27x |
| Company: PE -78.00 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.672 - 0.888 ( +/- 13.85%) |
| ATR Model: 14 days |
Forecast:
01:40 - $0.866
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.780 (1.30% ) |
| Volume | 0.0032 mill |
| Avg. Vol. | 0.149 mill |
| % of Avg. Vol | 2.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ERYP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ERYP
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Latest Press Releases
2021-09-06 16:05:00 - Press Release
Erytech To Present At The H.c. Wainwright 23rd Annual Global Investment Conference
Cambridge, ma (u.s.) and lyon (france), september 6, 2021 – erytech pharma (nasdaq & euronext: eryp), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its ceo, gil beyen, will present at the h.c. wainwright 23rd annual global investment conference. the conference will be held virtually with all participants joining remotely from september 13th - 15th, 2021.
2021-01-14 16:30:00 - Press Release
Erytech Announces First Patient Enrolled In A Phase 1 Investigator Sponsored Trial Of Eryaspase In First-line Pancreatic Cancer
Erytech announces first patient enrolled in a phase 1 investigator sponsored trial of eryaspase in first-line pancreatic cancer
2020-12-14 16:30:00 - Press Release
Erytech Completes Enrollment In Trybeca-1 Phase 3 Trial In Second-line Pancreatic Cancer
Lyon, france and cambridge, mass., dec. 14, 2020 (globe newswire) -- erytech pharma (nasdaq & euronext: eryp), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the trybeca-1 phase 3 trial in second-line pancreatic cancer.
2020-12-10 16:30:00 - Press Release
Erytech To Present At The Jmp Securities hematology Summit
Lyon, france and cambridge, mass., dec. 10, 2020 (globe newswire) -- erytech pharma (nasdaq & euronext: eryp), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that ceo, gil beyen, will present at t he jmp securities hematology summit tuesday december 15 th at 1: 3 0pm est /0 6 : 3 0pm gmt / 7 : 3 0pm cet . the format will be a “fireside chat” discussion hosted by jmp securities' reni benjamin.
2020-12-10 12:00:00 - Press Release
Monthly Information Related To Total Number Of Voting Rights And Shares Composing The Share Capital – November 30, 2020
Lyon, france, dec. 10, 2020 (globe newswire) -- article 223-16 of general regulation of french autoritÉ des marchÉs financiers lyon – france
Latest News
2023-05-13 22:17:10 - Seeking Alpha
Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
Erytech Pharma SA (NASDAQ:ERYP ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Gil Beyen - CEO Thibaut du Fayet - CEO, Pherecydes Pharma Didier Hoch - Chairman, Pherecydes Pharma Conference Call Participants Jacob Mekhael - Kempen & Co. Operator Thank you for standing by, and welcome to the conference call on the proposed merger between ERYTECH Pharma and Pherecydes Pharma. [Operator Instructions].
2023-05-09 08:11:12 - InvestorPlace
Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
Erytech Pharma (NASDAQ: ERYP ) stock is on the rise Tuesday after the company provided investors with a business update for Q1! First up is the company's planned merger with Pherecydes.
2022-11-22 10:24:03 - Seeking Alpha
ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q3 2022 Earnings Conference Call November 22, 2022 8:30 AM ET Company Participants Gil Beyen - CEO Eric Soyer - CFO and COO Conference Call Participants Boris Peaker - Cowen Operator Good morning, and thank you for standing by.
2022-10-05 13:32:15 - Zacks Investment Research
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-08-26 15:03:11 - Zacks Investment Research
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.
2022-05-13 11:18:03 - Seeking Alpha
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call Transcript
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Gil Beyen – Chief Executive Officer Eric Soyer – Chief Financial and Chief Operating Officer Dr. Iman El-Hariry – Chief Medical Officer Conference Call Participants Boris Peaker – Cowen and Company Jacob Mekhael – Kempen & Co Operator Good day, and thank you for standing by.
2022-04-25 09:31:32 - PennyStocks
Best Penny Stocks to Buy as April Ends? 3 to Watch Today
Here's what you need to know about trading penny stocks on April 25th The post Best Penny Stocks to Buy as April Ends? 3 to Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-25 07:15:04 - Benzinga
Why Erytech Pharma Are Shares Moving Higher Today
Erytech Pharma SA (NASDAQ: ERYP) has sold its US manufacturing facility to Catalent Inc (NYSE: CTLT) for $44.5 million. Catalent will acquire Erytech's commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, with 40 people.
2022-04-07 08:15:03 - Benzinga
Why Erytech Pharma Shares Are Rising Today
Erytech Pharma SA (NASDAQ: ERYP) says that the results from the NOPHO sponsored Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL) patients are published in the British Journal of Haematology. The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological.
2022-03-14 13:33:04 - Seeking Alpha
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2021 Results - Earnings Call Transcript
